<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940706-2-00076</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Centers for Disease Control and Prevention</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Cooperative Research and Development Agreement  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[CRADA 94&hyph;001] </RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Centers for Disease Control and Prevention (CDC), Public Health Service, HHS.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Centers for Disease Control and Prevention (CDC), National Center for Infectious Diseases, announces the opportunity for potential collaborators to enter into a Cooperative Research and Development Agreement (CRADA) for the further development, refinement, and validation of three interrelated technologies: (1) The Exchangeable Template Reaction (ETR), a method to assemble synthetic genes, (2) the construction of hepatitis C virus (HCV) specific ``mosaic'' proteins composed of immunodominant antigenic epitopes, and (3) differential HCV diagnostic tests. It is anticipated that these and any new technologies or inventions which may arise from this CRADA will be licensed to the collaborator with whom the CRADA is made.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Because CRADAs are designed to facilitate the development of scientific and technological knowledge into useful, marketable products, a great deal of freedom is given to Federal agencies in implementing collaborative research. The CDC may accept staff, facilities, equipment, supplies, and money from the other participants in a CRADA; CDC may provide staff, facilities, equipment, and supplies to the project. There is a single restriction in this exchange: CDC MAY NOT PROVIDE FUNDS to the other participants in a CRADA. This opportunity is available until 30 days after publication of this notice. Respondents may be provided a longer period of time to furnish additional information if CDC finds this necessary.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Technical: Howard A. Fields, Ph.D., Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop G&hyph;14, Atlanta, GA 30333, telephone (404) 639&hyph;2335.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Business: Lisa Blake-DiSpigna, Technology Transfer Representative, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop C&hyph;19, Atlanta, GA 30333, telephone (404) 639&hyph;3227.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The goal of this CRADA is to bring to market HCV-specific technologies that will improve public health. CDC will provide intellectual insight and experimental design protocols to: (1) Improve the efficiency of ETR, (2) construct ``mosaic'' proteins for HCV that have immunodiagnostic and potential vaccine relevance, and (3) evaluate synthetic peptides containing antigenic epitopes as reagents to discriminate recent from late infections or that may predict outcome of HCV infection. CDC will design and conduct feasibility experiments for each of the project areas and will contribute in the preparation of serologic panels to validate various test formats. The CRADA partner will prepare all synthetic peptides and oligonucleotides as necessary for each project area, prepare monospecific and monoclonal antibodies whenever appropriate, and purify antigens from recombinant lysates as needed. The collaborator will utilize its expertise in market research to evaluate the commercialization of the technologies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Respondents should provide evidence of expertise in the development and evaluation of diagnostic assays, evidence of experience in commercialization of diagnostics products, and supporting data (e.g., publications, proficiency testing, certifications, resumes, etc.) of qualifications for the principle investigator who would be involved in the CRADA. The  <!-- PJG 0012 frnewline --> respondent will develop the final research plan in collaboration with CDC.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Applicant submissions will be judged according to the following criteria:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Expertise in diagnostic virolgoy;  <!-- PJG 0012 frnewline --> 2. Evidence of scientific credibility;  <!-- PJG 0012 frnewline --> 3. Evidence of commitment and ability to develop innovative designs for diagnostic assays and/or vaccines;  <!-- PJG 0012 frnewline --> 4. Evidence of preparing synthetic peptides and oligonucleotides;  <!-- PJG 0012 frnewline --> 5. Evidence of a strong engineering department to design automated equipment; and,  <!-- PJG 0012 frnewline --> 6. Evidence of an existing infrastructure to commercialize on successful technologies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> This CRADA is proposed and implemented under the 1986 Federal Technology Transfer Act, Public Law 99&hyph;502 (15 U.S.C. 3710).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The responses must be made to: Lisa Blake-Despigna, Technology Transfer Coordinator, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop C&hyph;19, Atlanta, GA 30333. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: June 29, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Arthur C. Jackson,  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;16281 Filed 7&hyph;5&hyph;94; 8:45 am]  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4163&hyph;18&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            